MARKET

SCNX

SCNX

Scienture Holdings, Inc
NASDAQ
0.4718
-0.0023
-0.49%
After Hours: 0.4606 -0.0112 -2.37% 19:25 08/20 EDT
OPEN
0.4600
PREV CLOSE
0.4741
HIGH
0.4806
LOW
0.4600
VOLUME
363.46K
TURNOVER
--
52 WEEK HIGH
2.600
52 WEEK LOW
0.2382
MARKET CAP
19.37M
P/E (TTM)
-0.2538
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SCNX last week (0810-0814)?
Weekly Report · 4d ago
Analyst Maintains Buy Rating and $1.50 Price Target on Scienture Amid Strong Early Commercialization for Arbli and Rezenopy
TipRanks · 5d ago
Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M
Seeking Alpha · 6d ago
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Benzinga · 6d ago
*Scienture Holdings 2Q Loss/Shr 7c >SCNX
Dow Jones · 6d ago
*Scienture Holdings 2Q Rev $343,639 >SCNX
Dow Jones · 6d ago
Scienture Holdings: Q2 Earnings Snapshot
Barchart · 08/13 17:37
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Benzinga · 08/12 11:46
More
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Webull offers Scienture Holdings Inc stock information, including NASDAQ: SCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNX stock methods without spending real money on the virtual paper trading platform.